Tetraphase Pharmaceu
(TTPH)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 161,365 | 118,214 | 128,159 | 142,086 | 162,076 |
| Receivables | 3,565 | 2,682 | 1,703 | 1,789 | 745 |
| TOTAL | $170,423 | $126,013 | $133,691 | $150,457 | $169,513 |
| Non-Current Assets | |||||
| PPE Net | 1,424 | 1,529 | 1,467 | 1,054 | 932 |
| Other Non-Current Assets | 199 | 199 | 199 | 199 | 199 |
| TOTAL | $1,623 | $1,728 | $1,666 | $1,253 | $1,131 |
| Total Assets | $172,046 | $127,741 | $135,357 | $151,710 | $170,644 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,893 | 6,918 | 3,595 | 2,555 | 3,621 |
| Accrued Expenses | 12,888 | 12,124 | 11,771 | 7,685 | 6,214 |
| TOTAL | $22,563 | $20,590 | $16,217 | $11,495 | $10,912 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 782 | 1,548 | 851 | 1,255 | 1,077 |
| Other Non-Current Liabilities | 119 | 134 | 148 | 162 | 176 |
| TOTAL | $119 | $134 | $148 | $162 | $176 |
| Total Liabilities | $22,682 | $20,724 | $16,365 | $11,657 | $11,088 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,571 | 2,553 | 1,898 | 1,853 | 1,845 |
| Common Shares | 51 | 40 | 38 | 37 | 37 |
| Retained earnings | -438,408 | -408,401 | -376,590 | -347,132 | -324,671 |
| TOTAL | $149,364 | $107,017 | $118,992 | $140,053 | $159,556 |
| Total Liabilities And Equity | $172,046 | $127,741 | $135,357 | $151,710 | $170,644 |